Stocks in medical sector have been in the limelight for quite some time. Yesterday, I researched over 400 stocks in the medical sector.[More...]

The indices had another strong start to the week with another strong gap up at the opening on very positive futures.  They then backed and filled, retested early lows and then rallied steadily to mid-afternoon when they reached their peaks for the day.  They pulled back into the last hour, but in the last 15-mintues snapped back sharply to close near the highs for the day on the Nasdaq 100 and not far from them on the S&P 500. Net on the day the Dow gained 114.95 to 9286.56, just 12 points off its high.  The S&P 500 was up 15.15 to 1002.63, closing over 1000 for the first time since November.  That was less than a point from its highs.  The Nasdaq 100 advanced 24.76 to 1628.12, just pennies from its high. Advance-declines were 5 to 1 positive on New York and 2/1/2 to 1 positive on Nasdaq.   Up/down volume was about 7 1/2 to 1 positive on New York on total volume of just under 1.2[More...]

Affymetrix (NASDAQ:AFFX) is getting lots of commentary followin better-than-expected Q2 results: - Piper Jaffray is upgrading their rating to Overweight from Neutral and raising their target to $11 (prev. $5) Firm notes the upgrade reflects a favorable valuation, improving operational metrics and favorable revenue mix. They note the management is successfully restructuring the company's manufacturing cost base (and now turning their attention to operating expenses), the valuation (currently trading at 1.0x 2010 EV/Rev estimate) and the changing mix of business away from markets where they are less competitive (i.e. GWAS) and shifting resources toward markets that benefit Affy's products (such as pharmacogenomics). At this point, Piper believes it is far too premature[More...]

As promised during his election campaign, President Obama seems to be swiftly acting on the US healthcare reform.[More...]